Heron Therapeutics director granted 53,960 RSUs

Heron Therapeutics director Christian Waage received a new equity award in the form of restricted stock units.

Rhea-AI Filing Summary

Heron Therapeutics director Christian Waage received a new equity award in the form of restricted stock units. On January 30, 2026, he was granted 53,960 shares of common stock at a price of $0 per share.

The award was structured as restricted stock units that vest in full on January 30, 2027, with each unit representing the right to receive one share of common stock. Following this grant, Waage beneficially owned 53,960 shares directly.

Insider Trade Summary

Grant/Award: 53,960 shares

Grant/Award 1 txn

Insider Christian Waage

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	53,960	$0.00	$0.00

Holdings After Transaction: Common Stock — 53,960 shares (Direct)

Footnotes (1)

1. F1. The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Heron Therapeutics (HRTX) director Christian Waage receive?

Christian Waage received a grant of 53,960 restricted stock units of Heron Therapeutics common stock. Each unit represents the right to receive one share, providing him with equity-based compensation tied directly to the company’s stock performance.

When do Christian Waage’s 53,960 Heron Therapeutics restricted stock units vest?

The 53,960 restricted stock units granted to Christian Waage vest in full on January 30, 2027. Vesting means he will become entitled to receive the underlying common shares on that date, assuming all applicable conditions are satisfied.

What price did Christian Waage pay for his Heron Therapeutics restricted stock units?

The restricted stock units were granted at a price of $0 per share. This indicates they were an equity incentive award, rather than shares purchased in the open market, aligning director compensation with the company’s long-term stock performance.

How many Heron Therapeutics shares does Christian Waage own after this Form 4 transaction?

After the reported transaction, Christian Waage beneficially owned 53,960 shares of Heron Therapeutics common stock. These shares are held directly in his name, reflecting the full amount of the restricted stock unit grant reported in the filing.

What role does Christian Waage hold at Heron Therapeutics (HRTX)?

Christian Waage serves as a director of Heron Therapeutics. The reported restricted stock unit grant represents part of his director compensation, designed to align his interests with shareholders through ownership of the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 10:00 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christian Waage

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NC 27518

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		53,960(1)	A	$0	53,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

	/s/Kathryn Lester Attorney-in-fact for Christian Waage	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.